Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics Inc
(NQ:
KYMR
)
36.25
-3.19 (-8.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kymera Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
December 14, 2022
Business wins are shining the spotlight on these two companies.
Via
The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
December 14, 2022
Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month.
Via
InvestorPlace
Why Is SOFI Stock Up 7% Today?
December 14, 2022
SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares.
Via
InvestorPlace
Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22
December 14, 2022
Crown Electrokinetics (CRKN) stock is on the move Wednesday as investors prepare for the company's upcoming shareholder meeting.
Via
InvestorPlace
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
December 14, 2022
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase.
Via
InvestorPlace
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
December 14, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Kymera Therapeutics
December 06, 2022
Via
Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
November 22, 2022
Via
Benzinga
Where Kymera Therapeutics Stands With Analysts
November 08, 2022
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter:
Via
Benzinga
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
December 14, 2022
Via
Benzinga
US Stocks Higher Ahead Of Fed Decision
December 14, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday
Via
Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
December 14, 2022
The company is working on protein degradation in cancer and inflammatory diseases.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 14, 2022
Via
Benzinga
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
December 14, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
5 Analysts Have This to Say About Kymera Therapeutics
November 08, 2022
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter:
Via
Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
November 04, 2022
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Recap: Kymera Therapeutics Q3 Earnings
November 03, 2022
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
December 13, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
December 12, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
December 11, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
December 06, 2022
Via
Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
December 06, 2022
Via
Benzinga
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
December 01, 2022
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
November 08, 2022
Upgrades
Via
Benzinga
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
November 03, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
November 03, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
October 20, 2022
Company also presenting at upcoming investor conferences
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
October 13, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate
September 15, 2022
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.